within Pharmacolibrary.Drugs.ATC.L;

model L01EK03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.79,
    Cl             = 0.07533333333333332,
    adminDuration  = 600,
    adminMass      = 1.34,
    adminCount     = 1,
    Vd             = 0.171,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.007666666666666667,
    Tlag           = 9.0
  );

  annotation(Documentation(
    info ="<html><body><p>Tivozanib is a selective vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC). It is approved for use in several countries, including the United States and the European Union.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in adult patients with advanced solid tumors and renal cell carcinoma following oral administration of tivozanib.</p><h4>References</h4><ol><li><p>Cotreau, MM, et al., &amp; Vargo, DL (2014). The effect of food on the pharmacokinetics of tivozanib hydrochloride. <i>Clinical pharmacology in drug development</i> 3(2) 158–162. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.76&quot;>10.1002/cpdd.76</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27128461/&quot;>https://pubmed.ncbi.nlm.nih.gov/27128461</a></p></li><li><p>Zayed, AL, et al., &amp; Qinna, NA (2023). HPLC methods for studying pharmacokinetics of tivozanib and in vitro metabolic interaction with dexamethasone in rat. <i>Journal of pharmaceutical and biomedical analysis</i> 232 115423–None. DOI:<a href=&quot;https://doi.org/10.1016/j.jpba.2023.115423&quot;>10.1016/j.jpba.2023.115423</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37146497/&quot;>https://pubmed.ncbi.nlm.nih.gov/37146497</a></p></li><li><p>Cotreau, MM, et al., &amp; Slichenmyer, W (2015). Effects of ketoconazole or rifampin on the pharmacokinetics of tivozanib hydrochloride, a vascular endothelial growth factor receptor tyrosine kinase inhibitor. <i>Clinical pharmacology in drug development</i> 4(2) 137–142. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.145&quot;>10.1002/cpdd.145</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27128217/&quot;>https://pubmed.ncbi.nlm.nih.gov/27128217</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01EK03;
